The mission of Mayo Translational PKD Center (MTPC) is to advance the understanding and reduce the individual and societal burden of PKD. The overall goal of MTPC is to develop Core facilities to support existing and stimulate new PKD research by Mayo and non-Mayo investigators and to facilitate the translation of basic research breakthroughs into improvements in clinical practice through the implementation of clinical trials. Since July 2010, the Administrative Core of the MTPC has: i) provided strong strategic and administrative oversight in the newly established PKD Research and Translation Core Center; ii) fostered the interaction and synergism of three, heavily used MTPC Biomedical Research Cores (Molecular Genetics and Biomarker Core, Model Systems Core, and Human Imaging Core), chosen as the most effective to achieve the Center's goals and building on the strength of the Mayo investigators; iii) strengthened the Internal Research Base and added a strong External Research Base of PKD investigators; iv) attracted and nurtured new PKD investigators through a dynamic Pilot and Feasibility Program; v) adopted software tools and developed metrics to monitor the performance of the Biomedical Research Cores and the Pilot and Feasibility Program; vi) implemented a vigorous Scientific Enrichment Program; and v) established relationships with internal and external partners to facilitate MTPC member access to resources. The Administrative Core leadership, provided by the Director and Co-Director, in conjunction with the Operations Committee, Executive Committee, Internal Advisory Committee, and External Advisory Committee, will continue to 1) Promote cooperative, successful scientific interactions among the multidisciplinary internal faculty and an extended faculty from 39 other institutions; 2) conduct periodic membership surveys to determine the needs of the internal and external members; 3) conduct periodic reviews of the Services provided by the Biomedical Research Cores of the MTPC to ensure that cutting edge technologies replace those no longer needed; 4) promote the communication and coordinate the activities of the three Biomedical Research Cores of the MTPC to ensure that they synergistically enhance the research capabilities of the members; 5) conduct periodic reviews of Core Use and involvement in Center Activities to modify the Research Base membership as needed; 6) provide budgetary and administrative management necessary for efficient, cost-effective accomplishment of Center goals and allocate resources commensurate with member needs; 7) ensure a successful Scientific Enrichment Program including weekly seminars, monthly conferences, periodic workshops, annual mini-symposia, visiting faculty program, mini-sabbaticals and communications via electronic media; 8) continue a Pilot and Feasibility Program funded equally by this grant and by the Mayo Foundation under the direction of the Pilot and Feasibility Program Director and the External Advisory Committee; 9) stimulate interest in PKD and provide career development opportunities for junior investigators through the NIH Summer Undergraduate Research Fellowship, NIH T32 training grant (T32) and other funding sources and by creating a forum for their research updates; 10) continue and expand existing cost-effective, scientific interactions between MTPC and the NIDDK-funded C-SiG, the Mayo CCaTS, and other NIH funded Centers.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK090728-07
Application #
9144761
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
7
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Boczek, Nicole J; Hopp, Katharina; Benoit, Lacey et al. (2018) Characterization of three ciliopathy pedigrees expands the phenotype associated with biallelic C2CD3 variants. Eur J Hum Genet 26:1797-1809
Lea, Wendy A; Parnell, Stephen C; Wallace, Darren P et al. (2018) Human-Specific Abnormal Alternative Splicing of Wild-Type PKD1 Induces Premature Termination of Polycystin-1. J Am Soc Nephrol 29:2482-2492
Wong, Annette T Y; Mannix, Carly; Grantham, Jared J et al. (2018) Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). BMJ Open 8:e018794
Cornec-Le Gall, Emilie; Torres, Vicente E; Harris, Peter C (2018) Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases. J Am Soc Nephrol 29:13-23
Torres, Vicente E; Chapman, Arlene B; Devuyst, Olivier et al. (2018) Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrol Dial Transplant 33:477-489
Higashihara, Eiji; Horie, Shigeo; Kinoshita, Moritoshi et al. (2018) A potentially crucial role of the PKD1 C-terminal tail in renal prognosis. Clin Exp Nephrol 22:395-404
Kline, Timothy L; Edwards, Marie E; Garg, Ishan et al. (2018) Quantitative MRI of kidneys in renal disease. Abdom Radiol (NY) 43:629-638
Chebib, Fouad T; Torres, Vicente E (2018) Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol 13:1765-1776
Erickson, Bradley J; Korfiatis, Panagiotis; Kline, Timothy L et al. (2018) Deep Learning in Radiology: Does One SizeĀ Fit All? J Am Coll Radiol 15:521-526
Lanktree, Matthew B; Haghighi, Amirreza; Guiard, Elsa et al. (2018) Prevalence Estimates of Polycystic Kidney and Liver Disease by Population Sequencing. J Am Soc Nephrol 29:2593-2600

Showing the most recent 10 out of 192 publications